NCT04341103Unknown不适用
AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience
适应症
试验速览
- 阶段
- 不适用
- 发起方
- CareDx
- 入组人数
- 500
- 主要终点
- Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19
研究概览
简要总结
The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19
详细描述
An observational case series of patients with solid organ transplants who have been admitted with suspected COVID-19 utilizing AlloSure dd-cf DNA to help guide immunosuppression management balancing the treatment of sepsis and avoiding allograft rejection.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed diagnosis of COVID-19
排除标准
- 未提供
结局指标
主要结局
Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19
时间窗: 6 months
AlloSure dd-cfDNA blood draw values
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting TransplantationTransplantationNCT04376775University Hospital, Bordeaux3,602
已完成
不适用
Immune Status in Solid Organ TransplantationOrgan TransplantsNCT01070901Dartmouth-Hitchcock Medical Center20
已完成
不适用
Randomized Controlled Trial of ImmuKnow in Liver TransplantationLiver DiseaseNCT01764581University of Bologna206
撤回
1 期
Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody CocktailCOVID-19Organ TransplantNCT05157997Northwell Health
Unknown
不适用
Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant RecipientsKidney TransplantationSARS-CoV-2 Acute Respiratory DiseaseVaccineNCT04969614West China Hospital300